The National Cancer Institute's Phase 0-I-II Prevention Clinical Trials Program (Consortia) performs early phase clinical trials to assess the safety, tolerability, and cancer preventive potential of agents and interventions of varying classes, many of which target molecules or processes known to be important during carcinogenesis.
The Cancer Data Access System (CDAS) is a web portal that facilitates access to the data recorded for the 2012 Consortia trials For some studies biospecimens may also be available. CDAS provides extensive public documentation for each study, including a trial summary, an overview of the data collected, and a searchable database of research projects and publications.
COVID-19 Memorandums for Division of Cancer Prevention Investigators
MEMORANDUMS
-
Date: May 8, 2020 -
Supported by the NCI DCP Phase 0-2 Cancer Prevention Clinical Trials Program
Date: March 27, 2020 -
Date: March 13, 2020
PLEASE NOTE: This is a reminder that infections occurring in subjects on clinical trials are considered adverse events, please see this additional guidance for reporting COVID-19 related adverse event.
News and Events
2023 “Investigators' and Site Coordinators' Opportunity for Research Excellence” (I-SCORE) HYBRID meeting
Date Posted: February 8, 2023
DCP/PREVENT-funded Project Presentations at AACR Virtual Annual Meeting I, April 9-15 2021
Date Posted: April 23, 2021